Compare GE Vernova Inc (GEV) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Natera Inc. Common Stock — how do they compare? GE Vernova Inc trades at $927.12 (market cap $267.41B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: GE Vernova Inc is far larger — about 4.7× Natera Inc. Common Stock's market cap, and GE Vernova Inc pays a 0.2% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 37 Days and Natera Inc. Common Stock for 0 Days on average.
| GEV | NTRA | |
|---|---|---|
Market Cap | $267.41B | $57.03B |
Volume | 1,900,074 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $1.17K | $425.64 |
52-Week Low | $547.96 | $179.42 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $257.08B | $56.18B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,004.04, up 0.73% with strong bullish momentum from technical indicators and positive analyst sentiment. The stock shows impressive fundamental performance with 2026 revenue projected at $41.4B and net income of $9.5B, representing a 23.03% profit margin. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and strong backlog growth to $176B, positioning the company to benefit from AI-driven power demand.
The outlook remains positive with 76% analyst buy ratings and a $1,270 consensus price target suggesting 26% upside potential. Key risks include valuation concerns with P/E of 28.79 and EV/EBITDA of 85.64 appearing elevated, along with execution challenges in the wind power segment. The stock's strong cash flow generation and positioning in the AI power infrastructure theme support continued growth prospects despite rich valuations.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
